228 related articles for article (PubMed ID: 31240550)
1. Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study.
Huang YT; Li CC; Chou YH; Ke HL; Chen CY
Int J Clin Pharm; 2019 Aug; 41(4):993-1003. PubMed ID: 31240550
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.
Adam S; Koch-Gallenkamp L; Bertram H; Eberle A; Holleczek B; Pritzkuleit R; Waldeyer-Sauerland M; Waldmann A; Zeissig SR; Rohrmann S; Brenner H; Arndt V
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13076. PubMed ID: 31050091
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
4. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.
Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
6. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
[TBL] [Abstract][Full Text] [Related]
7. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
8. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Lubeck DP; Grossfeld GD; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in Dutch men with prostate cancer.
Voerman B; Fischer M; Visser A; Garssen B; van Andel G; Bensing J
J Psychosoc Oncol; 2006; 24(2):49-64. PubMed ID: 17046806
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
[TBL] [Abstract][Full Text] [Related]
11. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
12. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
Hammerer PG; Wirth MP;
Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
[TBL] [Abstract][Full Text] [Related]
14. Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.
Kretschmer A; Ploussard G; Heidegger I; Tsaur I; Borgmann H; Surcel C; Mathieu R; de Visschere P; Valerio M; van den Bergh RCN; Marra G; Thibault C; Ost P; Gandaglia G; Tilki D;
Eur Urol Focus; 2021 Jul; 7(4):742-751. PubMed ID: 32089495
[TBL] [Abstract][Full Text] [Related]
15. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
16. Depression, Anxiety, and Their Association to Health-Related Quality of Life in Men Commencing Prostate Cancer Treatment at Tertiary Hospitals in Cape Town, South Africa.
Irusen H; Fernandez P; Van der Merwe A; Suliman S; Esterhuizen T; Lazarus J; Parkes J; Seedat S
Cancer Control; 2022; 29():10732748221125561. PubMed ID: 36112984
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy.
Yang BK; Crisci A; Young MD; Silverstein AD; Peterson BL; Dahm P
Urology; 2005 Jan; 65(1):120-5. PubMed ID: 15667876
[TBL] [Abstract][Full Text] [Related]
19. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
